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Antimicrobial practice
Monitoring serum concentrations for once-daily netilmicin dosing
regimens
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A once-daily dosing regimen for aminoglycosides is less expensive, at least as
effective and possibly less toxic than multiple-daily dosing regimens. Once-daily
dosing might also allow the frequency of measuring the serum concentrations of
these antibiotics to be reduced since two of the major objectives of monitoring, high
peak and low trough concentrations, are more likely to be achieved with this
regimen. A novel strategy for monitoring serum concentrations which relies on a
single sample obtained 8 h after a dose, as opposed to both trough and peak
samples, is evaluated here. Serum kinetics of netilmicin were studied prospecu'vely in
51 adult patients with initial serum creatinine concentrations of < 130 /imol/L who
were treated with a median daily dosage of 400 mg. Concentrations measured 8 h
after administration were within the target range of 1-5-6 mg/L in 113 of 134 dosing
intervals studied. Concentrations above and below this range correlated significantly
with higher and lower 24-h trough concentrations and areas under the curve
respectively. There was also a significant correlation between 8-h netilmicin concen-
trations and nephrotoxicity (P < 0-05); a relative increase of ^ 25% in the serum
creatinine concentration or an absolute increase of > 25 //mol/L was detected in 0
of 7 patients with an 8-h concentration of < 1-5 mg/L, in 3 of 33 patients (91%)
with an 8-h concentration of 1-5-6 mg/L and in 4 of 11 patients (36%) with an 8-h
concentration of > 6 mg/L. The results of this study suggest that adequate
information about serum netilmicin concentrations in patients receiving a once-daily
dose may be derived from a sample obtained 8 h after administration.
Introduction
For many years the total daily dosage of an aminoglycoside has been administered in
two or three divided doses. More recently, however, increasing numbers of experi-
mental and clinical studies have demonstrated that a once-daily dosing regimen might
be at least as effective and possibly less toxic (Bennett et al., 1979; Powell et ai, 1983;
Craig, Redington & Ebert, 1991; Gilbert, 1991). Such a significant modification of the
dosing regimen might also necessitate changes in current thinking regarding the
monitoring of the serum concentrations of these agents. Measuring both the peak and
trough concentrations has been advocated by both pharmacologists and clinicians in
order to ensure that therapeutic dosages are administered (Zaske et al., 1982; Wenk,
Vozeh & Follath, 1984). It is essential to achieve high peak concentrations since the
bactericidal activities of the aminoglycosides are concentration-dependent and the ratio
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of the peak concentration to the MIC correlates closely with therapeutic outcome
(Blaser et al., 1987; Moore, Lietman & Smith, 1987). Monitoring trough concentrations
is also undertaken to avoid drug accumulation which is usually the result of reduced
renal elimination; elevated trough concentrations have been associated with amino-
glycoside toxicity (Wenk et al., 1984).
To date, there have been no studies which have considered the issue of monitoring
serum concentrations specifically in relation to once-daily dosing regimens. In two
recent publications, it was proposed that aminoglycoside dosages in patients receiving
single daily doses should be reduced when the 24-h trough concentrations exceeded 2
mg/L (Parker & Davey, 1993; Prins et al., 1993). However, while a threshold concentra-
tion of this magnitude has been used routinely for multidose regimens, there is little
evidence to suggest that it is equally appropriate for once-daily regimens. Indeed, such
an approach would result in very high areas under the concentration vs time curve
(AUC) in patients with impaired renal function.
Monitoring both peak and trough serum concentrations is expensive and labour-
intensive. In addition, it is often difficult in clinical practice to obtain samples which
have been timed accurately, a factor which is particularly critical in relation to the peak
concentration (Blaser et al., 1985). Once-daily dosing of aminoglycosides may allow the
frequency of monitoring to be reduced. Administration of the total daily dosage in one
short infusion leads to peak concentrations which are at least two-fold greater than
those obtained when multiple-daily doses are administered i.e. the goal of a high peak
concentration to MIC ratio is more likely to be achieved; increasing the dosing interval
to 24 h also reduces the likelihood of drug accumulation. None the less, the need for
monitoring is not totally removed and remains necessary in order to detect significant
drug accumulation in patients with impaired renal function. Moreover, the peak
concentrations and AUCs might be significantly different in heterogeneous groups of
patients receiving standard aminoglycoside dosages because of larger inter-individual
variations in the distribution and elimination of these agents (Zaske et al., 1982; Wenk
et al., 1984). Savings in both manpower and laboratory costs would be realized if serum
monitoring required the collection of only a single serum sample during a dosing
interval. We have assessed the feasibility of such a strategy during the course of a
prospective clinical trial with netilmicin.
Patients and methods
Netilmicin serum concentrations were studied in 51 adult patients with intial serum
creatinine concentrations of < 130 /anol/L. Serum creatinine concentrations were
measured before starting therapy, on alternate days during the course of therapy and
following completion of therapy; the concentrations determined before and after
treatment were used to calculate changes during the intervening period. A clinically
significant increase in the creatinine concentration was suggestive of nephrotoxicity
which was defined in both relative (an increase of > 25%) and absolute (an increase of
> 25 /imol/L) terms. Blood samples for the determination of netilmicin concentrations
were obtained on three occasions during a 24-h dosing interval — immediately after a
60-min infusion and 8 and 24 h after starting the infusion. For each patient, this was
undertaken on the day after therapy was initiated and every second or third day
thereafter until treatment was terminated. Patients initially received dosages of 6 mg/kg
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body weight in a single daily dose; these were subsequently adjusted, if necessary, in
order to achieve 8-h serum concentrations of between 1-5 and 6 mg/L.
Netilmicin serum concentrations were determined by a fluorescence polarization
assay (TDx, Abbott Laboratories). The coefficient of variation of the assay was < 10%
for concentrations of > 1 mg/L (Joos, Liithy & Blaser, 1989) and the results
(means ±S.D.) for spiked specimens containing 0-5, 0-25 and Omg/L were 0-52 ±0-03,
0-31 ±004 and 007±0-06 mg/L, respectively. Measurements of < 0-3 mg/L were
taken as 0-2 mg/L for the purpose of calculating the AUC and the mean trough
concentrations. The AUC was calculated according to the trapezoidal rule.
All statistical calculations were performed with the computer program StatView II
(Abacus Concepts Inc., Berkeley, CA, USA). The significance of correlations between
8-h concentrations of < 1-5 mg/L and low 24-h trough concentrations (< 0-5 mg/L)
and between 8-h concentrations of > 6 mg/L and high 24-h trough concentrations
O 0-5 mg/L) was calculated by the two-tailed Chi-square test. The statistical signifi-
cance of differences between AUCs was analyzed by the two-tailed Kruskal-Wallis test
and the significance of an increased incidence of nephrotoxicity in relation to 8-h
concentrations of > 6 mg/L was analyzed by the Chi-square test with continuity
correction. For a statistical analysis of trough and peak concentrations and AUCs,
box-plots were constructed. Diagnostic sensitivity was calculated by dividing the
number of patients in whom nephrotoxicity was diagnosed correctly according to the
criteria used by the total number of patients who actually developed nephrotoxicity,
Diagnostic specificity was calculated by dividing the number of patients without
nephrotoxicity according to the diagnostic criteria by the total number of patients who
did not develop nephrotoxicity.
Results
The daily dosages administered to patients ranged from 150-600 mg with a median of
400 mg. A total of 134 intervals between doses were monitored. Peak and trough
concentrations were categorized in relation to the 8-h determinations. In the box-plots
(Figures 1-3), the boxes define the boundaries within which the 25th, 50th and 75th
percentiles fall while the 10th and 90th percentiles are represented by the lower and
upper stems respectively; the notches represent the 95% confidence bands about the
median. The box-plots in Figures 1 and 2 show the frequency distributions of the
netilmicin trough and peak concentrations respectively. The 8-h concentrations were
< 1-5 mg/L in 9 of the 134 (6-7%) intervals and > 6 mg/L in 12 of the 134 (9%)
intervals (Table I). There was no correlation between peak and 8-h concentrations.
However, there was a statistically significant correlation between 8-h concentrations of
< 1-5 mg/L and low trough concentrations, all 9 of which were < 0-5 mg/L (P < 0-05),
and between 8-h concentrations of > 6 mg/L and high trough concentrations, 11 of 12
of which were > 0-5 mg/L (P < 0001). The three categories of 8-h concentrations
(< 1-5 mg/L, 1-5-6-0 mg/L and > 6-0 mg/L) also differed significantly in terms of the
AUC (P < 0-001) (Figure 3 and Table I).
The netilmicin dosages administered to seven patients were increased from a mean of
360 mg to a mean of 500 mg when the initial 8-h concentrations were found to be < 1-5
mg/L. In five of these seven patients, the effects of the increases were evaluated at the
next dosing interval when it was observed that the mean peak serum concentration and
mean AUC had increased from 16 to 27 mg/L and from 80 to 139 mg.h/L respectively.
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Flgnre 1. Box-plots displaying 24-h netilmicin trough concentrations for seven patients with 8-h serum
concentrations of < 1-5 mg/L, 33 patients with 8-h concentrations of 1-5-6 mg/L and 11 patients with 8-h
concentrations of > 6 mg/L.
For the purpose of assessing nephrotoxicity, patients were categorized as follows:
those with at least one 8-h concentration which was < 1-5 mg/L; those for whom all
8-h determinations fell between 1-5 and 6 mg/L; and those with at least one 8-h
concentration of > 6 mg/L (Table II). The incidences of nephrotoxicity in the three
groups were 0%, 9-1% and 36% respectively, regardless of whether the relative or
absolute endpoint was used. The incidence of nephrotoxicity in patients in the third
category (those with at least one 8-h concentration of > 6 mg/L) was significantly
higher than the incidences in the other two categories (P < 005).
1-5-6-0
8-h serum concentration (mg/L)
>6-0
Flgnre 2. Box-plots displaying netilmicin peak concentrations for seven patients with 8-h serum concentra-
tions of < 1-5 mg/L, 33 patients with 8-h concentrations of 1-5—6 mg/L and 11 patients with 8-h
concentrations of > 6 mg/L.
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Table I. Peak and trough netilmicin serum concentrations and AUCs in relation to
8-h scrum concentrations
Variable
No. (%) of monitored dosage
intervals
Mean ( ± S . D . ) dosages
(mg/day)
Mean ( ± S . D . ) peak
concentrations (mg/L)
Mean ( ± S . D . ) trough
concentrations (mg/L)
Mean ( ± S . D . ) AUC (h.mg/L)'
8-h
<
9
391
21-5
0-2
99
netilmicin
1-5
(6-7)
(±55)
(±88)
(±0-1)-
(±34)
serum concentration (mg/L)
1-5-6-0
113 (84-3)
388 (±96)
21-3 (±6-3)
0-4 ( + 0-3)
127 (±30)
> 6 0
12 (9-0)
357 (±94)
21-7 (±6-6)
1-5 (±1-3)*
184 (±40)
"Significantly lower (P < 005) than the other two categories.
•Significantly higher (P < frOOl) than the other two categories.
'P < 0-001 for differences between categories.
The sensitivities and specificities for the various criteria which were considered as
potential diagnostic markers of nephrotoxicity were 0-57 and 0-84 respectively for 8-h
netilmicin concentrations of > 6 mg/L, 0-71 and 064 respectively for 24-h trough
concentrations of > 05 mg/L, 0-43 and 091 for 24-h trough concentrations of > 1
mg/L, 043 and 098 respectively for 24-h trough concentrations of > 2 mg/L and 0-29
and 043 for peak concentrations of > 24 mg/L.
Discussion
It is presently standard practice to monitor the serum concentrations of patients
receiving aminoglycosides both before (trough) and after (peak) a dose. In this study,
300
250
,200
150
100
50-
I T x
<l-5 1-5-6-0
8-h serum concentration (mg/L)
> 6 0
Figure 3. Box-plots displaying areas under the concentration vs time curve (AUC) for netilmicin in seven
patients with 8-h serum concentrations of < 1-5 mg/L, 33 patients with 8-h concentrations of 1-5—6 mg/L and
11 patients with 8-h concentrations of > 6 mg/L.
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Table II. Increase in serum crcatinine concentrations during therapy in relation to
8-h netilmicin serum concentrations
8-h netilmicin serum concentration (mg/L)
<l-5 1-5-60 > 6 0
No. of patients 7 33 11
Mean (±S.D.) pre-treatment
serum creatinine
concentration (//mol/L) 84-4 (±17-3) 93 (±18-5) 102 (± 17-8)
Mean (±S.D.) post-treatment
serum creatinine
concentration Oanol/L) 904 (±21-3) 90-5 (±20-4) 142 (±98)
No. (%) of patients whose
serum creatinine
concentrations increased by
>25/imol/L 0(0) 3(9-1) 4(36-4)-
No. (%) of patients whose
serum creatinine
concentrations increased by
> 25% 0 (0) 3 (9-1) 4 (36-4)-
' P < 005 compared with the other cateories.
we have assessed the suitability of measuring the serum concentration in a single
sample obtained 8 h after the start of a 1 -h infusion in patients with an initial serum
creatinine concentration of < 130 /zmol/L who were receiving a once-daily dose of
netilmicin. The target concentrations for this sample were defined as 1-5-6 mg/L; this
range is three-fold higher than that which is currently considered acceptable at our
institution for a trough concentration in patients receiving a thrice-daily dosing
regimen. The 8-h concentrations determined in the present study were within the target
range for the majority (84%) of patients. Concentrations which were above and below
this target were predictive of high and low trough concentrations and AUCs respec-
tively. An 8-h concentration which exceeded 6 mg/L was associated with a 4-8-fold
increase in the risk of nephrotoxicity; the sensitivity of this criterion was greater than
those for 24-h trough concentrations of > 1 or > 2 mg/L and for peak concentrations
of > 24 mg/L and the specificity was greater than those for 24-h trough concentrations
of > 05 mg/L and for peak concentrations of > 24 mg/L.
The results reported here suggest that the proposed target range is sufficiently broad
to obviate the need for frequent changes in dosages but is also sufficiently narrow to
enable dosing regimens which provide either very low or very high serum concentra-
tions to be identified. However, we are not suggesting that achieving uniform serum
kinetics should be the ultimate goal of monitoring treatment with aminoglycosides.
Indeed, it might be of greater benefit to some patients to be assigned aminoglycoside
regimens which give rise to serum concentrations which are higher or lower than those
which are usually obtained with standard dosing regimens; for example, higher serum
concentrations might be therapeutically advantageous in patients with infections which
are associated with particularly poor prognoses, such as those caused by Pseudomonas
aeruginosa, despite the increased risk of toxicity. Investigations which have demon-
strated the importance of a high peak to MIC ratio for the aminoglycosides (Blaser et
al. 1987; Moore et al., 1987) and experimental studies which suggest that antibiotic
concentrations should exceed the MIC, except for the duration of the post-antibiotic
effect (Vogelman et al., 1988), support the recommendation that, when devising
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aminoglycoside dosing guidelines, account must also be taken of the susceptibility of
the pathogen.
Currently-available commercial assays are designed to yield reliable results which fall
within the range of the peak and trough concentrations encountered in most patients
receiving multiple daily doses of the aminoglycosides. Peak serum samples obtained
from patients receiving once-daily doses must be first diluted in order to ensure that
concentrations fall within this range, a procedure which affects the accuracy of the
assay. The accurate determination of trough concentrations requires assay techniques
with very low limits of sensitivity; most existing assays are not sufficiently precise to
give reliable results for the low concentrations which are usually present in 24-h trough
samples. Serum concentrations measured 8 h after the onset of short infusions, on the
other hand, fall within the ranges of reproducibility and accuracy of most commercial
assays. As this probably applies equally to specimens taken either a few hours earlier or
later, the choice of 8 h may, therefore, seem arbitrary. However, if samples are obtained
during the second half of the 24-h dosing interval, it is essential to ensure that the assay
result is available in sufficient time to allow the dosage of the subsequent dose to be
adjusted if necessary. Such samples may provide only limited information since half-
lives increase towards the end of a 24-h interval because of redistribution from deep
compartments (y-phase). Consequently, a two-compartment model will not reliably fit
the serum kinetics for all patients over the entire 24-h period (Wenk et al., 1984). It may
be difficult, therefore, to adjust dosages which are based on concentrations determined
during the y-phase. In addition, serum concentrations in samples which were obtained
during the second half of the 24-h interval and which fall below the limit of sensitivity
of the assay do not allow patients with normal rates of elimination to be reliably
distinguished from those with very rapid elimination rates, such as children and
patients with burns. Viscoli et al. (1991) studied serum concentrations in children
receiving single daily doses of amikacin (20 mg/kg) and recorded 6-h concentrations of
< 3 mg/L in 13 of 16 cases, despite mean peak concentations of 73 mg/L. The detection
of 8-h concentrations which are low makes it possible to increase the dosages in
patients with correspondingly low AUCs; in the present study, this facilitated dosage
increases in seven of the 51 patients. Experimental data suggest that high peak
concentrations and AUCs are associated with superior response rates (Blaser et al.,
1987; Moore et al., 1987; Vogelman et al., 1988; Craig et al., 1991).
Virtually every aspect of the aminoglycosides has been extensively investigated to
date. More than 36,000 papers have been indexed under 'aminoglycosides' or 'anti-
biotics-aminoglycosides' since 1966 in MEDLINE, the bibliographical database of the
National Library of Medicine, Washington, USA. However, whether traditional,
multiple-daily dosing regimens lead to suboptimal therapy compared with a once-daily
regimen is an issue which remains to be resolved. Even greater controversy surrounds
the monitoring of serum concentrations.
A recent re-evaluation of the therapeutic range for the aminoglycosides was critical
of the scientific basis for current recommendations (McCormack & Jewesson, 1992). It
is unlikely, however, that, within the next few years, sufficient experimental and clinical
data will have been accumulated to resolve the questions of optimal timing and
concentration ranges in relation to the monitoring of serum concentrations in patients
receiving once-daily doses of aminoglycosides, irrespective of whether their renal
function is normal or not. The present study has successfully demonstrated that there is
a significant association between nephrotoxicity and 8-h serum concentrations, the
criterion proposed here for monitoring treatment with the aminoglycosides. However,
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we were unable to confirm that this parameter can also be used to ensure that serum
concentrations which optimize the therapeutic efficacy of the aminoglycosides are more
likely to be achieved: indeed, obtaining sufficient evidence for this in prospective,
ethically non-controversial clinical trials will be a considerable challenge.
In conclusion, the administration of the total daily dosage of netilmicin in one short
infusion yielded high peak concentrations and concomitant increases in the ratio of the
peak concentration to the MIC of the pathogen. Furthermore, increasing the dosing
interval to 24 h minimized the potential for drug accumulation. The determination of 8-
h concentrations in patients receiving once-daily dosing regimens has been shown to be
useful in identifying patients with either low AUCs or increased risks of nephrotoxicity.
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